Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan-Dec:9:23247096211013193.
doi: 10.1177/23247096211013193.

A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge

Affiliations
Case Reports

A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge

Stephen Bell et al. J Investig Med High Impact Case Rep. 2021 Jan-Dec.

Abstract

Crescentic glomerulonephritis, also known as rapidly progressive glomerulonephritis, is a syndrome characterized by progressive and rapid deterioration of renal function over the course of weeks to months. Oliguria, hematuria, azotemia, and hypertension are characteristic features of this condition. Crescentic glomerulonephritis is further classified according to the staining pattern on immunofluorescence. In rare instances, a mixed pattern of injury is encountered as in the case of double antibody-positive rapidly progressive glomerulonephritis (RPGN). This case illustrates the challenge in treatment of double antibody-positive RPGN in an elderly female with no previous renal disease. The patient was found to be positive for anti-GBM antibody and MPO-ANCA. Treatment was initially targeted against MPO-ANCA as the biopsy was most consistent with this process; however, the patient failed to respond to treatment and was subsequently transitioned to oral cyclophosphamide directed against anti-GBM disease. In cases of doubly antibody-positive RPGN with anti-GBM disease and ANCA-associated vasculitis, initial treatment should focus on inducing remission of anti-GBM disease as double antibody-positive disease often presents with the aggressive morbidity and mortality seen in anti-GBM disease, and the chronic risk of relapse seen in ANCA-mediated vasculitis.

Keywords: ANCA-associated vasculitis; anti-glomerular basement membrane disease; crescentic glomerulonephritis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Ultrasound of right kidney, which measures 10.4 × 4.3 × 4.4 cm. There is minor renal cortical thinning asymmetrically involving the mid-pole cortex. The cortex is mildly hyperechoic. No sonographic evidence of calculus or ureteral dilatation.
Figure 2.
Figure 2.
Renal biopsy specimen. Trichrome stain of the kidney biopsy revealing approximately 30% scarring (A). Hematoxylin and eosin stain showing collapsing glomeruli with associated increase in size of Bowman’s space (B and C). Extravasation of fibrin into Bowman’s can be appreciated (C). Jones Silver stain highlighting the basement membrane (D). Immunofluorescent staining shows linear deposits of immunoglobulin G in the basement membrane (E).

Similar articles

Cited by

References

    1. Arimura Y, Muso E, Fujimoto S, et al.. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20:322-341. doi:10.1007/s10157-015-1218-8 - DOI - PMC - PubMed
    1. Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014;13:723-729. doi:10.1016/j.autrev.2014.02.007 - DOI - PubMed
    1. Smith C, Dhaliwal G, Saint S, Farkash EA, Garg P. Double trouble. N Engl J Med. 2019;381:1854-1860. doi:10.1056/NEJMcps1810654 - DOI - PubMed
    1. Cancarevic I, Malik BH. Use of rituximab in management of rapidly progressive glomerulonephritis. Cureus. 2020;12:e6820. doi:10.7759/cureus.6820 - DOI - PMC - PubMed
    1. McAdoo SP, Tanna A, Hrušková Z, et al.. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92:693-702. doi:10.1016/j.kint.2017.03.014 - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources